What's Going On With Biodexa Pharmaceuticals Stock?
What's Going On With Biodexa Pharmaceuticals Stock?
Biodexa Pharmaceuticals (NASDAQ:BDRX) stock is trading higher. The company on Tuesday announced progress towards the treatment of Familial Adenomatous Polyposis.
Biodexa Pharmicals（納斯達克股票代碼：BDRX）股價走高。該公司週二宣佈了在治療家族性腺瘤性息肉病方面取得的進展。
What Happened: Biodexa, a clinical-stage biopharmaceutical company dedicated to acquiring and developing innovative solutions for diseases with unmet medical needs, has announced positive statistically significant findings from the Phase 2 clinical trial of eRapa in Familial Adenomatous Polyposis.
發生了什麼：Biodexa是一家臨床階段的生物製藥公司，致力於爲醫療需求未得到滿足的疾病收購和開發創新解決方案，該公司宣佈了eRapa在家族性腺瘤性息肉病中的2期臨床試驗中得出的具有統計學意義的積極發現。
During the trial, patients were divided into three groups of 10, receiving different doses of the treatment over 12 months. Endoscopic exams were conducted at the start and after six months to evaluate safety, tolerability and changes in polyp size.
在試驗期間，患者分爲三組，每組10人，在12個月內接受不同劑量的治療。在開始時和六個月後進行了內窺鏡檢查，以評估安全性、耐受性和息肉大小的變化。
The results of the experiment showed eRapa, an oral tablet formulation of rapamycin, appeared safe and well-tolerated with a significant 24% reduction in the total polyp burden at six months compared with baseline, as well as an overall 83% non-progression rate.
實驗結果顯示，雷帕黴素口服片劑製劑eRapa看起來安全且耐受性良好，與基線相比，六個月後的息肉總負擔顯著減少了24％，總體非進展率爲83％。
The results of the Phase 2 trial based on six month data are scheduled for presentation at the 2024 Digestive Disease Week annual meeting in Washington D.C.
基於六個月數據的2期試驗結果計劃在華盛頓特區舉行的2024年消化疾病週年會上公佈。
How To Buy BDRX Stock
如何購買 BDRX 股票
By now you're likely curious about how to participate in the market for Biodexa Pharmaceuticals – be it to purchase shares, or even attempt to bet against the company.
現在，你可能對如何參與Biodexa Pharmicals的市場感到好奇——無論是購買股票，還是試圖對該公司下注。
Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy "fractional shares," which allows you to own portions of stock without buying an entire share. In the case of Biodexa Pharmaceuticals, which is trading at $2.28 as of publishing time, $100 would buy you 43.86 shares of stock.
購買股票通常通過經紀賬戶完成。您可以在此處找到可能的交易平台列表。許多股票允許您購買 “部分股票”，這使您無需購買整股即可擁有部分股票。就Biodexa Pharmicals而言，截至發佈時的交易價格爲2.28美元，100美元將爲您購買43.86股股票。
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to "go short" a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.
如果你想對一家公司下注，這個過程會更加複雜。您需要訪問期權交易平台或經紀商，該經紀人將允許您通過向您借出股票來賣出股票來 “做空” 一股股票。可以在此資源中找到做空股票的過程。否則，如果您的經紀人允許您交易期權，您可以買入看跌期權，也可以以高於當前股票交易價格的行使價賣出看漲期權——無論哪種方式，它都允許您從股價下跌中獲利。
BDRX Price Action: At the time of writing, Biodexa Pharmaceuticals shares were up 78.4% at $2.20, according to Benzinga Pro.
BDRX價格走勢：根據Benzinga Pro的數據，在撰寫本文時，Biodexa Pharmicals的股價上漲了78.4％，至2.20美元。
譯文內容由第三人軟體翻譯。